Exploring the Link Between Cardiorenal and Metabolic Diseases

Overview

Journal Healthcare (Basel)

Specialty Health Services

Date 2023 Nov 14

PMID 37957976

Authors

Luis DMarco

Ana Checa-Ros

Affiliations

Soon will be listed here.

Abstract

The close link between metabolic diseases, such as obesity and diabetes mellitus, and cardiorenal disease can be attributed not only to direct risk factors, such as hypertension, but also to the intricate interplay of various pathophysiological processes [...].

Citing Articles

Sex Differences in Biochemical Analyses, Cardiometabolic Risk Factors and Their Correlation with CRP in Healthy Mexican Individuals.

Brambila-Tapia A, Gonzalez-Gomez A, Carrillo-Delgadillo L, Saldana-Cruz A, Davalos-Rodriguez I J Pers Med. 2024; 14(9).

PMID: 39338158 PMC: 11433147. DOI: 10.3390/jpm14090904.

References

Chung E, Trinh K, Li J, Hahn S, Endre Z, Rogers N . Biomarkers in Cardiorenal Syndrome and Potential Insights Into Novel Therapeutics. Front Cardiovasc Med. 2022; 9:868658. PMC: 9163439. DOI: 10.3389/fcvm.2022.868658. View

Bello A, Alrukhaimi M, Ashuntantang G, Basnet S, Rotter R, Douthat W . Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. Kidney Int Suppl (2011). 2019; 7(2):122-129. PMC: 6341007. DOI: 10.1016/j.kisu.2017.07.007. View

Rosca C, Sharma A, Nisulescu D, Otiman G, Duda-Seiman D, Morariu S . Prevalence of Cardio-Embolic Brain Complications in Permanent and Paroxysmal Atrial Fibrillation Patients. Healthcare (Basel). 2023; 11(2). PMC: 9858915. DOI: 10.3390/healthcare11020175. View

DMarco L, Checa-Ros A, Gamero D, Soto C, Salazar J, Nava M . Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation. Healthcare (Basel). 2023; 11(1). PMC: 9818894. DOI: 10.3390/healthcare11010072. View

Tomas-Simo P, DMarco L, Romero-Parra M, Tormos-Munoz M, Saez G, Torregrosa I . Oxidative Stress in Non-Dialysis-Dependent Chronic Kidney Disease Patients. Int J Environ Res Public Health. 2021; 18(15). PMC: 8345537. DOI: 10.3390/ijerph18157806. View

Handelsman Y, Butler J, Bakris G, DeFronzo R, Fonarow G, Green J . Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023; 37(2):108389. DOI: 10.1016/j.jdiacomp.2022.108389. View

Zhang R, Mamza J, Morris T, Godfrey G, Asselbergs F, Denaxas S . Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals. BMC Med. 2022; 20(1):63. PMC: 8822817. DOI: 10.1186/s12916-022-02234-2. View

Perretta F, Jaurretche S . Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?. Healthcare (Basel). 2023; 11(4). PMC: 9957019. DOI: 10.3390/healthcare11040449. View

Ortiz A, Germain D, Desnick R, Politei J, Mauer M, Burlina A . Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018; 123(4):416-427. DOI: 10.1016/j.ymgme.2018.02.014. View

10.

Levin A, Tonelli M, Bonventre J, Coresh J, Donner J, Fogo A . Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017; 390(10105):1888-1917. DOI: 10.1016/S0140-6736(17)30788-2. View

11.

Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl U . Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2014; 38(3):420-8. DOI: 10.2337/dc14-1096. View

12.

Herzog C, Asinger R, Berger A, Charytan D, Diez J, Hart R . Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80(6):572-86. DOI: 10.1038/ki.2011.223. View

13.

Forman D, Butler J, Wang Y, Abraham W, OConnor C, Gottlieb S . Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43(1):61-7. DOI: 10.1016/j.jacc.2003.07.031. View

14.

Chen C, Yang X, Lei Y, Zha Y, Liu H, Ma C . Urinary Biomarkers at the Time of AKI Diagnosis as Predictors of Progression of AKI among Patients with Acute Cardiorenal Syndrome. Clin J Am Soc Nephrol. 2016; 11(9):1536-1544. PMC: 5012473. DOI: 10.2215/CJN.00910116. View

15.

Germain D . Fabry disease. Orphanet J Rare Dis. 2010; 5:30. PMC: 3009617. DOI: 10.1186/1750-1172-5-30. View

16.

Montomoli M, Roca L, Rivera M, Fernandez-Prado R, Redondo B, Camacho R . Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study. Healthcare (Basel). 2022; 10(12). PMC: 9778700. DOI: 10.3390/healthcare10122566. View

17.

Jha V, Arici M, Collins A, Garcia-Garcia G, Hemmelgarn B, Jafar T . Understanding kidney care needs and implementation strategies in low- and middle-income countries: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2016; 90(6):1164-1174. DOI: 10.1016/j.kint.2016.09.009. View

18.

Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson O . Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study. J Am Soc Nephrol. 2016; 28(5):1631-1641. PMC: 5407735. DOI: 10.1681/ASN.2016090964. View

19.

Nichols G, Romo-LeTourneau V, Vupputuri S, Thomas S . Delays in anti-hyperglycaemic therapy initiation and intensification are associated with cardiovascular events, hospitalizations for heart failure and all-cause mortality. Diabetes Obes Metab. 2019; 21(7):1551-1557. DOI: 10.1111/dom.13683. View

20.

Andreadi A, Bellia A, Di Daniele N, Meloni M, Lauro R, Della-Morte D . The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: A target for new therapies against cardiovascular diseases. Curr Opin Pharmacol. 2021; 62:85-96. DOI: 10.1016/j.coph.2021.11.010. View